Cascadian Therapeutics Inc (CASC) Given Average Rating of “Hold” by Brokerages
Cascadian Therapeutics Inc (NASDAQ:CASC) has been given an average recommendation of “Hold” by the seven ratings firms that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.00.
Separately, Zacks Investment Research raised shares of Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Monday, November 13th.
Cascadian Therapeutics (NASDAQ CASC) opened at $4.07 on Tuesday. The firm has a market cap of $205.78, a PE ratio of -3.04 and a beta of 2.29. Cascadian Therapeutics has a 12 month low of $3.18 and a 12 month high of $4.97.
Cascadian Therapeutics (NASDAQ:CASC) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.01. During the same quarter in the previous year, the business posted ($0.09) EPS. analysts predict that Cascadian Therapeutics will post -1.27 earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Cascadian Therapeutics by 24.1% during the second quarter. Vanguard Group Inc. now owns 1,767,681 shares of the biopharmaceutical company’s stock worth $6,567,000 after buying an additional 343,838 shares during the period. Dimensional Fund Advisors LP boosted its stake in Cascadian Therapeutics by 423.0% during the third quarter. Dimensional Fund Advisors LP now owns 511,899 shares of the biopharmaceutical company’s stock worth $2,094,000 after buying an additional 414,019 shares during the period. State Street Corp lifted its position in shares of Cascadian Therapeutics by 1,113.7% during the second quarter. State Street Corp now owns 411,299 shares of the biopharmaceutical company’s stock worth $1,527,000 after purchasing an additional 377,410 shares in the last quarter. Northern Trust Corp lifted its position in shares of Cascadian Therapeutics by 415.5% during the second quarter. Northern Trust Corp now owns 382,469 shares of the biopharmaceutical company’s stock worth $1,420,000 after purchasing an additional 308,270 shares in the last quarter. Finally, P.A.W. Capital Corp acquired a new stake in shares of Cascadian Therapeutics during the third quarter worth about $982,000. 80.33% of the stock is owned by institutional investors.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.